Annexon Biosciences’ ANX005 Shows Promise in GBS Phase 3 Trial
Company Announcements

Annexon Biosciences’ ANX005 Shows Promise in GBS Phase 3 Trial

An update from Annexon Biosciences (ANNX) is now available.

Annexon’s Phase 3 clinical trial of ANX005 in GBS patients yielded promising results, with the drug showing a significant improvement on the GBS-disability scale and other key secondary outcomes, such as muscle strength and reduced need for artificial ventilation. The study, conducted in areas with higher GBS prevalence and limited treatment access, supports the drug’s safety and paves the way for real-world evidence collection and FDA submission. These developments hold potential for addressing the substantial healthcare burden of GBS, a condition currently lacking FDA-approved treatments.

For detailed information about ANNX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyAnnexon presents Phase 2 Vision Preservation data with ANX007 in dry AMD
TheFlyAnnexon reports inducement grants under Nasdaq listing rule
TheFlyAnnexon added to Q4 2024 Tactical Ideas List at Wells Fargo
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App